EVENTS | VIEW CALENDAR
Contract tech roundup
In late September came news from Montrium, an industry provider of electronic trial master file (eTMF) solutions, that EastHORN Clinical Services had selected Montrium's eTMF Connect to optimize its clinical programs and TMF management. EastHORN, a leading European contract research organization (CRO), will implement the eTMF platform to increase transparency to enable greater collaboration with sponsors, improve compliance and provide greater value for its customers.
“We firmly believe that technology solutions will give us a competitive advantage in the crowded CRO market. The value a powerful eTMF solution could have on the advancement of our clinical projects and the increased transparency a centralized tool could have on collaboration with our partners were important considerations in deciding on the Montrium system,” said Dr. Malgorzata Szerszeniewska, CEO of EastHORN Clinical Services. “It was also important that we selected an eTMF tool that not only supported us with a robust functionality set but was incredibly intuitive and easy to use."
“Contract research organizations play an increasingly critical role in the execution of clinical trials, and have emerged as integral stakeholders in the compilation of trial master files and electronic submissions," said Paul Fenton, president and CEO of Montrium. “We are extremely excited to have been selected as a strategic partner of EastHORN to help them empower their continued growth.”
Meanwhile, Crown Bioscience (CrownBio) announced recently that their integrated oncology platform has facilitated the preclinical development of a HERA-GITRL immunotherapeutic from Apogenix. HERA-GITRL is an immunotherapy showing antitumor activity in non-small cell lung cancer and head and neck cancer.
The data derived from studies using CrownBio’s portfolio were first presented by Apogenix in an oral presentation at the AACR 2017 Annual Meeting. These data showed the immunotherapy’s potential clinical utility and demonstrated the benefits of using CrownBio’s platform in preclinical efficacy testing.
“It is our mission to deliver innovative technologies so that companies like Apogenix can leverage and accelerate their research,” said Laurie Heilmann, a senior vice president at Crown. “Our scientific oncology platform uniquely enhances preclinical immunotherapy development and will continue to deliver valuable insights that drive new discoveries in this area.”
Finally, full-service technology-led CRO Cmed presented its encapsia clinical data suite at Mobile in Clinical Trials and DPharm: Disruptive Innovations to Advance Clinical Trials 2017. Cmed designed encapsia to streamline the capture, management and reporting of clinical data.
“We combine the practical experience of a full-service CRO with the latest technology knowhow to inspire and drive real progress throughout the clinical trial process and, ultimately, achieve higher-quality outcomes and efficiencies for today’s studies,” said Cmed CEO David Connelly.